Lucie Ellis

@LucieLEllis

Executive Editor at In Vivo lucie.ellis@informa.com

London, UK
Vrijeme pridruživanja: ožujak 2011.

Tweetovi

Blokirali ste korisnika/cu @LucieLEllis

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @LucieLEllis

  1. proslijedio/la je Tweet
    prije 13 sati

    Leo Sets Up For A David & Goliath Showdown In Atopic Dermatitis

    Poništi
  2. proslijedio/la je Tweet
    4. velj

    . have not bought cancer asset this year as economic model showed market potential was not big enough to pay for the deal head of m&a, to acquire an asset market size must be big enough

    Poništi
  3. 4. velj

    Is a new technology business joining Roivant Sciences' fleet? "VantAI"? Focus to be on image recognition technology for biopharma.

    Poništi
  4. proslijedio/la je Tweet
    4. velj

    Due diligence when acquiring assets: 1) focus on studying science; mostly biotech, gene therapy, large molecules, work is now complex, 2nd aspect is environmental; heritage, animal rights, data protection, risks understood 3) work with/trust team

    Poništi
  5. 4. velj

    Philippe Loper-Fernandes "there are plenty of ways to engage external experts on due diligence ... must understand what a deal means for the business moving forward"

    Poništi
  6. 4. velj

    Novartis' Nigel Sheail, head of M&A and BD&L talks to audience at about due diligence lessons post data manipulation issues and importance of understanding the science

    Poništi
  7. proslijedio/la je Tweet
    3. velj

    Pipeline Watch: Phase III Readouts In Atopic Dermatitis, Ischemic Stroke

    Poništi
  8. proslijedio/la je Tweet

    Congratulations . How will you top this latest aducanumab gem? (quote via )

    Prikaži ovu nit
    Poništi
  9. 30. sij

    Next week I will be hosting a fireside chat with Cedric Ververken, CEO of ConfoTherapeutics, at Congress on the topic of win/win early-stage biotech partnerships. Any burning questions you have for him? I look forward to an interesting discussion...

    Poništi
  10. proslijedio/la je Tweet
    30. sij

    China Coronavirus Cases Up Sharply As Pharma Rushes To Aid

    Poništi
  11. proslijedio/la je Tweet
    29. sij

    made $390m in 2019, approved midyear in children under 2. It's on a partial trial hold in older patients. I talked to President Lennon on the relationship with FDA, the clinical hold and expansion in gene therapy

    Poništi
  12. proslijedio/la je Tweet
    16. sij

    My round up is available for free and we don't do that a lot so take advantage. big pharma business strategy, deals, drug pricing and snippets from some of the industry leaders I talked to.

    Poništi
  13. 16. sij

    In Vivo's Deals Of The Year contest is now live! Go and pick your winners.

    Poništi
  14. proslijedio/la je Tweet
    16. sij

    Latest installment with all you need to know from J.P. Morgan Day 3: Skyrizi Momentum Builds, What's Next For Amarin, Viatris Debuts And More

    Poništi
  15. 15. sij
    Poništi
  16. 15. sij
    Poništi
  17. proslijedio/la je Tweet
    15. sij

    Vas Narasimhan gets biggest laugh in exchange with 's Francesco De Rubertis who asks 3 CEOs to name their next M&A targets. Vas jokes: I've a question for you: do you feel biotech evaluation expectations have got completely out of hand?!

    Poništi
  18. proslijedio/la je Tweet
    14. sij

    Day 1 round-up from team; notably, update on Zolgensma reimbursement: no payers to date have used annuity model, instead preferring outcomes-based payment tied to death or permanent ventilation ($sub)

    Poništi
  19. proslijedio/la je Tweet
    13. sij

    Interview: KaNDy Menopause Therapy Hits Sweet Spot

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·